Each capsule contained 0 6 ml of oil, giving 360 mg of linolenic and 3 42 g of linoleic acid daily. Group B received eight capsules of identical appearance containing 0 6 ml of oleic acid. Group C received 11*5 g per day of linoleic acid in the form of a spread. Group D had a similar spread providing 4 g of oleic acid per day. Groups A and C thus received active treatment and Groups B and D acted as controls. Patients underwent detailed neurological assessment on admission to the trial and at six-week intervals thereafter. Overall disability was scored on the Kurtzke Disability Status Scale4 and the site, duration, and severity of any relapses were recorded.
The four groups did not differ significantly in respect of age, sex, or duration of illness. As shown in the table there was no statistically significant difference between the groups in the number of patients who improved, deteriorated, or remained unchanged. Some patients, although suffering from chronic progressive disease, did have exacerbations and there was no difference between the attack rates in the four groups. The relapse score, as defined by Miller et al,3 was slightly higher for patients in Group C but the difference was not statistically significant. 
Results

Discussion
In this trial patients in Groups C and D received respectively linoleic acid and oleic acid in doses that were similar to those used in the trial of Miller et al,3 although the vehicle was different. Half the treated patients were on Naudicelle capsules, which provide a convenient method of administering linoleic acid and at the same time contain linolenic acid, which is the parent acid of the long-chain polyunsaturated fatty acid docosahexaenoic acid. This acid, together with arachidonic acid formed from linoleic, is important in the membrane phospholipids of human brain.5
Although in the trial of Miller et al3 all the patients were suffering from acute remitting disease, we included also patients with chronic progressive disease. The two groups were studied separately within the trial because it seemed possible that they might respond differently: plaques in chronic progressive disease may be more stable than in acute relapsing and therefore less liable to be influenced by treatment. Our results refer only to patients in the chronic progressive group and show no benefit as the result of the treatment with either linoleic acid or a mixture of linoleic and linolenic acids. The rate and severity of deterioration have not been significantly altered and the relapse rate, small though it is in this part of the trial, has not been influenced.
The results of the section of the trial concerning patients with acute remitting disease will be reported later.
We are indebted to the Multiple Sclerosis Society of Great Britain and Northern Ireland for financing the trial, including the purchase of Naudicelle capsules. We thank also Van den Berghs Limited for supplying gratis the spreads containing linoleic and oleic acid. Finally we thank all our neurological colleagues for referring patients to us. Fistulisation of shunt vasculature: a unique approach to fistula development Some centres prefer fistulas and others arteriovenous shunts for haemodialysis blood access.'-3 Those patients who develop acute renal failure, however, do not have time for the fistula to mature before their initial need for haemodialysis.4
To preserve alternate blood access sites for the future, we have used the placement of an arteriovenous shunt in the peripheral radial artery-cephalic vein location with subsequent anastomosis of this same vasculature for fistula formation. We describe our technique and tabulate the results in three patients who required acute haemodialysis via a shunt initially and subsequently used the fistula for long-term haemodialysis treatment.
Surgical techniques
Because these patients required relatively immediate haemodialysis a Buselmeier arteriovenous shunt was inserted in the radial artery-cephalic vein location at the wrist.' 2 The patients were haemodialysed for three to five weeks on the arteriovenous shunt, during which their veins enlarged remarkably. The shunt was removed and a fistula created through end-to-end anastomosis of the shunted vessels. All three showed excellent venous development and dilatation immediately after the fistula procedure. One patient had return of sufficient renal function to obviate the immediate need for haemodialysis, although the creatinine concentration remained above 796 jumol/l (9 mg/ 100 ml), indicating a need for haemodialysis in the future.
The others were to be transferred to a haemodialysis centre which preferred the arteriovenous fistula for blood access. One fistula was used immediately for dialysis and the others were not used until three days and three months after the procedure. At present the fistulas continue to function at three, seven, and eleven months after their placement. There were no aneurysms, infections, or steal syndromes (see figure) .
Use of shunt vasculature for A-V fistula formation. (A) Buselmeier arteriovenous shunt placed in radial artery-cephalic vein location for acute haemodialysis. (B) Incision to expose and mobilise radial artery and cephalic vein at cannulation sites. (C) Construction of fistula from shunt vasculature by end-to-end anastomosis of radial artery and cephalic vein previously used for Buselmeier shunt cannulation.
Discussion
Every effort should be made to conserve vascular access sites in uraemic patients. There is always the possibility of primary access failure during the long course of these patients' chronic dialysis or subsequent recurrent renal failure in those who reject renal transplants. Some patients may, however, require access to the blood stream for the treatment of acute renal failure or acute exacerbations early in the course of their chronic renal failure. It has been common practice to temporise with intermittent femoral vein catheterisation, leg shunts, or peritoneal dialysis before the maturation of fistulas in those haemodialysis centres which prefer A-V fistulas. These procedures are not without their problems as the repeated catheterisation of the femoral vein may cause bleeding or embolism.5 The placement of the leg shunt, which some consider undesirable, exhausts a blood access site which may be useful for the patient in the future. Lastly, peritoneal dialysis may not be readily accomplished in some patients who have had recent abdominal surgery, multiple abdominal fistulas, or extreme adhesive peritonitis.
The technique described here provides a good compromise, in that those patients with acute renal failure may undergo early haemodialysis with a shunt. The vasculature which is enlarged by the fast flow of the shunt may then be converted to a fistula which can be used immediately for haemodialysis. I Buselmeier, T J, et al, Surgery, 1973, 73, 512. 2 Buselmeier, T J, et al, ASAIO, 1973, 19, 25. 3Quinton, W E, Dillard, D, and Scribner, B H, ASAIO, 1960, 6, 104. 
Early antenatal diagnosis of small open spina bifida lesions
The measurement of x-fetoprotein (ax-FP)in amniotic fluid is generally a reliable technique for the early antenatal diagnosis of neural tube defects.' It may, however, present difficulties if the fetus has only a small open spina bifida.2 We have produced evidence that a careful examination of the morphology of the amniotic fluid cells, particularly those cells that adhere rapidly to glass or plastic surfaces in culture, can help in making such diagnoses.' We report here two cases that illustrate this point.
Case 1
A 24-year-old mother, para 0-+ 1, with no history of affected children had three sequential x-FP values above the 95th percentile of the normal range (see table) . Amniocentesis at 19 weeks gave an amniotic fluid a-FP concentration of 32-8 mg/l. The total cell count was 50 x 106/1; 25 3 x 106/1 were viable. There was no blood cell contamination. Nine per cent of the viable cells were adherent to glass after 20 hours' incubation and all these cells had an abnormal morphology.3 The differential cell count showed that 49 % ofadherent cells were large vacuolated cells, 140o were long bipolar cells, and 9 % had multiple filamentous pseudopodia, while 28 0%O of the nuclei were contained in vacuolated giant multinucleated cells.
A second amniocentesis at 20 weeks gave an o-FP level of 24-2 mg/l. The total cell count was 51 x 106/1, of which 16 4>. 106/1 were viable. There were 1-3 x 109 red blood cells/l, of which 200 were fetal; 6 5 % of the viable cells were adherent, and while all these showed abnormal morphology (nonepithelioid), the long bipolar vacuolated cells were no longer present.
In view of the marginally raised amniotic fluid oc-FP concentrations the pregnancy was allowed to go to term. The outcome was an infant with a severe lumbar myelocele, who died after four days.
Case 2
A 26-year-old mother, para 2 + 0, with no history of affected children had three sequential a-FP values above the 95th percentile of the normal range. Amniocentesis at 19 weeks, after ultrasound scan, gave an amniotic fluid ot-FP value of 29 8 mg/l (see table) . The total cell count was 45 4 o 106/1, of which 18 x 106/1 were viable. The liquor was contaminated with 2-3 < 109 red blood cells/l, with 10 of fetal origin. Cellular adherence was less than 3°. Most of these cells were small with eccentrically placed nuclei, the remaining few nuclei being present in multinucleate cells which had no vacuolation or cytoplasmic inclusions. These cells are found only where the placenta has been traversed by the needle during amniocentesis.3 Serum ac-FP, amniotic fluid xc-FP, and proportions of rapidly adherent cells A second amniocentesis at 20 weeks gave an oc-FP level of 22-0 mg/I. The total cell count was 58 3 101/l, of which 20 106/1 were viable. There were 2-4 109 red blood cells/I, 10",, being fetal. Cellular adherence was less than 1 O.. There were no cells with abnormal morphology, the very few cells that adhered to the coverslip being epithelioid. In view of the similarity of the a-FP concentrations to those in case 1, however, it was decided to terminate the pregnancy. The fetus had no neural tube defect or any other sign of external or internal abnormality.
Comment
In each of the two cases described here there were three serum oc-FP values above the 95th percentile of the normal range and two amniotic fluid values above the defined upper limit of normal.4 In particular the matched amniotic fluid values at 19 and 20 weeks were virtually indistinguishable. The small amount of fetal blood contamination in case 2, represented by about 2 x 109 fetal red blood cells/l, could have contributed little to the amniotic fluid r-FP concentration.
The results of cellular adherence studies were, however, more discriminating. In case 1 both amniocentesis samples yielded abnormal proportions of rapidly adhering cells with morphology characteristic of a neural tube defect.: In case 2 the first amniocentesis sample showed some adherent cells, but their morphology suggested that the placenta had been traversed rather than that the fetus was abnormal.:' Examination of the second amniocentesis sample confirmed the suggestion that the fetus was normal, in that fewer than 1 0/ of adherent cells were seen and these had a normal (epithelioid) morphology. I Brock, D J H, British Medical Bulletin, 1976 , 32, 16. 2 Laurence, K M, et al, Lancet, 1976 
Induction of sex hormone binding globulin by phenytoin
In collecting material for a reference distribution of sex hormone binding globulin (SHBG) concentration, we identified a man who had an SHBG concentration considerably above that of the rest of the male population. After excluding thyroid or hepatic diseases, which are known to raise SHBG concentrptions,l the only abnormality remaining which could have possibly caused the high SHBG concentration was epilepsy, for which he was receiving phenytoin. To check the possibility of phenytoin-induced increase in SHBG concentration we decided to study the SHBG concentration in women with epilepsy treated with phenytoin (Difhydan or Fenantoin).
